Search

Displaying results 7461 - 7470 of 10000 in total
  1. Drug

    2-Hydroxylpropyl-beta-cyclodextrin

    go.drugbank.com/drugs/DB15146
    Investigational

    Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).

    Synonyms: 2-Hydroxypropyl-b-cyclodextrin, 2-hydroxypropyl-β-cyclodextrinCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Dextromethadone

    go.drugbank.com/drugs/DB15198
    Investigational

    Dextromethadone is under investigation in clinical trial NCT00588640 (Study of D-Methadone in Patients With Chronic Pain).

    Synonyms: D-methadone
  3. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    [A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal

    Categories: MATE 2-K Inhibitors, MATE 1 Inhibitors
  4. Drug

    Menaquinone

    go.drugbank.com/drugs/DB15381
    Investigational

    Menaquinone is under investigation in clinical trial NCT01533441 (Vitamin K2 Intervention in Patients With Vitamin K Antagonists).

    Categories: Vitamin K 2, Vitamin K
  5. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    Pafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum [A242572] within a range of 760 nm to 785 nm, with a peak absorption … It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.

    Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household setting
  6. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  7. Drug

    Ferric chloride

    go.drugbank.com/drugs/DB15536
    Approved

    Mixtures: Addamel N, ADDAMEL N
  8. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.

    Synonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamideCategories: MATE 1 Inhibitors, MATE 2 Inhibitors
  9. Drug

    Cobaltous sulfate

    go.drugbank.com/drugs/DB15760
    Investigational

    Mixtures: NUTRAGESTA ®, NUTRAGESTA ®
  10. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). … [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798]

    Synonyms: (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride, 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamideCategories: P-glycoprotein inhibitors, P-glycoprotein substrates